Where Are Biotech ETFs Headed After Q4 Earnings?

After facing difficulties last year following the rise in interest rates and a slowdown in merger activities, biotech companies are seeing a turnaround driven by attractive valuations and AI-led advances in medicine.The S&P Biotechnology Select Industry Index has gained 4.10% over the past year and 1.30% month to date.According to Financial Times, biotech firms are swiftly tapping into U.S. equity markets. Drug developers raised $6.2 billion in the markets in January, marking the highest amount raised since ...